These approaches apply mainly to solid tumors as myeloma, melanoma, and liposarcoma, although some trials have also been applied to acute myeloid leukemia (AML) (for details, see Therapies Directed to wt-p53 Re-Activation). The gene discussed is TP53; the disease is plasma cell myeloma.